Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Novel Chitohexaose Analog Protects Young and Aged mice from CLP Induced Polymicrobial Sepsis.

Das P, Panda SK, Agarwal B, Behera S, Ali SM, Pulse ME, Solomkin JS, Opal SM, Bhandari V, Acharya S.

Sci Rep. 2019 Feb 27;9(1):2904. doi: 10.1038/s41598-019-38731-3.

2.

Treatment and Prevention of Recurrent Clostridium difficile Infection with Functionalized Bovine Antibody-Enriched Whey in a Hamster Primary Infection Model.

Heidebrecht HJ, Weiss WJ, Pulse M, Lange A, Gisch K, Kliem H, Mann S, Pfaffl MW, Kulozik U, von Eichel-Streiber C.

Toxins (Basel). 2019 Feb 6;11(2). pii: E98. doi: 10.3390/toxins11020098.

3.

Pharmacological, Toxicological, and Dose Range Assessment of OG716, a Novel Lantibiotic for the Treatment of Clostridium difficile-Associated Infection.

Pulse ME, Weiss WJ, Kers JA, DeFusco AW, Park JH, Handfield M.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e01904-18. doi: 10.1128/AAC.01904-18. Print 2019 Apr.

PMID:
30670434
4.

In Vivo Efficacy of Novel Monobactam LYS228 in Murine Models of Carbapenemase-Producing Klebsiella pneumoniae Infection.

Weiss WJ, Pulse ME, Nguyen P, Growcott EJ.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02214-18. doi: 10.1128/AAC.02214-18. Print 2019 Apr.

PMID:
30642927
5.

Antibiotic-Induced Dysbiosis Predicts Mortality in an Animal Model of Clostridium difficile Infection.

Burdet C, Sayah-Jeanne S, Nguyen TT, Hugon P, Sablier-Gallis F, Saint-Lu N, Corbel T, Ferreira S, Pulse M, Weiss W, Andremont A, Mentré F, de Gunzburg J.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00925-18. doi: 10.1128/AAC.00925-18. Print 2018 Oct.

6.

OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections.

Kers JA, DeFusco AW, Park JH, Xu J, Pulse ME, Weiss WJ, Handfield M.

PLoS One. 2018 Jun 12;13(6):e0197467. doi: 10.1371/journal.pone.0197467. eCollection 2018.

7.

Mutacin 1140 Lantibiotic Variants Are Efficacious Against Clostridium difficile Infection.

Kers JA, Sharp RE, Defusco AW, Park JH, Xu J, Pulse ME, Weiss WJ, Handfield M.

Front Microbiol. 2018 Mar 16;9:415. doi: 10.3389/fmicb.2018.00415. eCollection 2018.

8.

Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis.

Weiss WJ, Pulse ME, Nguyen P, Peterson K, Silva J, Simecka JW, Valtierra D, Sabet M, Griffith DC.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01439-17. doi: 10.1128/AAC.01439-17. Print 2018 Jan.

9.

Protection of Hamsters from Mortality by Reducing Fecal Moxifloxacin Concentration with DAV131A in a Model of Moxifloxacin-Induced Clostridium difficile Colitis.

Burdet C, Sayah-Jeanne S, Nguyen TT, Miossec C, Saint-Lu N, Pulse M, Weiss W, Andremont A, Mentré F, de Gunzburg J.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e00543-17. doi: 10.1128/AAC.00543-17. Print 2017 Oct.

10.

Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?

Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, Hujer KM, Marshall EK, Rudin SD, Perez F, Wilson BM, Wasserman RB, Chikowski L, Paterson DL, Vila AJ, van Duin D, Kreiswirth BN, Chambers HF, Fowler VG Jr, Jacobs MR, Pulse ME, Weiss WJ, Bonomo RA.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02243-16. doi: 10.1128/AAC.02243-16. Print 2017 Apr.

11.

In vivo assessment of SMT19969 in a hamster model of clostridium difficile infection.

Weiss W, Pulse M, Vickers R.

Antimicrob Agents Chemother. 2014 Oct;58(10):5714-8. doi: 10.1128/AAC.02903-14. Epub 2014 Jul 14.

12.

Antigen-pulsed bone marrow-derived and pulmonary dendritic cells promote Th2 cell responses and immunopathology in lungs during the pathogenesis of murine Mycoplasma pneumonia.

Dobbs NA, Zhou X, Pulse M, Hodge LM, Schoeb TR, Simecka JW.

J Immunol. 2014 Aug 1;193(3):1353-63. doi: 10.4049/jimmunol.1301772. Epub 2014 Jun 27.

13.

Perturbation of Staphylococcus aureus gene expression by the enoyl-acyl carrier protein reductase inhibitor AFN-1252.

Parsons JB, Kukula M, Jackson P, Pulse M, Simecka JW, Valtierra D, Weiss WJ, Kaplan N, Rock CO.

Antimicrob Agents Chemother. 2013 May;57(5):2182-90. doi: 10.1128/AAC.02307-12. Epub 2013 Mar 4.

14.

Corticotropin-releasing hormone receptor-1 and 2 activity produces divergent resistance against stress-induced pulmonary Streptococcus pneumoniae infection.

Kim BJ, Kayembe K, Simecka JW, Pulse M, Jones HP.

J Neuroimmunol. 2011 Aug 15;237(1-2):57-65. doi: 10.1016/j.jneuroim.2011.06.016. Epub 2011 Jul 20.

15.

Small molecule inhibitors of Staphylococcus aureus RnpA alter cellular mRNA turnover, exhibit antimicrobial activity, and attenuate pathogenesis.

Olson PD, Kuechenmeister LJ, Anderson KL, Daily S, Beenken KE, Roux CM, Reniere ML, Lewis TL, Weiss WJ, Pulse M, Nguyen P, Simecka JW, Morrison JM, Sayood K, Asojo OA, Smeltzer MS, Skaar EP, Dunman PM.

PLoS Pathog. 2011 Feb 10;7(2):e1001287. doi: 10.1371/journal.ppat.1001287.

16.

Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.

Endimiani A, Hujer KM, Hujer AM, Pulse ME, Weiss WJ, Bonomo RA.

Antimicrob Agents Chemother. 2011 Jan;55(1):82-5. doi: 10.1128/AAC.01198-10. Epub 2010 Nov 1.

17.

Simultaneous determination of rifampicin and levofloxacin concentrations in catheter segments from a mouse model of a device-related infection by liquid chromatography/electrospray ionization tandem mass spectrometry.

Bao D, Truong TT, Renick PJ, Pulse ME, Weiss WJ.

J Pharm Biomed Anal. 2008 Mar 13;46(4):723-7. doi: 10.1016/j.jpba.2007.11.023. Epub 2007 Nov 26.

PMID:
18178051
18.
19.

Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins.

Kim IH, Combrink KD, Ma Z, Chapo K, Yan D, Renick P, Morris TW, Pulse M, Simecka JW, Ding CZ.

Bioorg Med Chem Lett. 2007 Mar 1;17(5):1181-4. Epub 2006 Dec 12.

PMID:
17189695

Supplemental Content

Support Center